Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
29 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251229117640/en/QurAlis-Confirms-Signal-of-Target-Engagement-in-ALS-Patients-in-Phase-1-Clinical-Trial-of-QRL-101-a-Potentially-Best-in-Class-Selective-Kv7.27.3-Ion-Channel-Opener
18 Dec 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-12-18/quralis-invited-to-present-at-44th-annual-jp-morgan-healthcare-conference
02 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251202434479/en/QurAlis-to-Present-Data-From-its-Phase-1-Clinical-Trial-of-QRL-101-a-Potential-Best-in-Class-Selective-Kv7.27.3-Ion-Channel-Opener-at-American-Epilepsy-Society-2025-Annual-Meeting
20 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251120380958/en/QurAlis-to-Participate-in-Piper-Sandler-37th-Annual-Healthcare-Conference
10 Nov 2025
// BUSINESS WIRE
https://www.businesswire.com/news/home/20251110510651/en/QurAlis-Announces-Appointment-of-Manoj-Malhotra-M.D.-as-Chief-Medical-Officer
03 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251103871526/en/QurAlis-to-Participate-in-Upcoming-Investor-Conferences-in-November
Drugs in Development
Details:
Under the licensing agreement, QurAlis explore the biology of FXS to determine and confirm relevant targets that could enable antisense oligonucleotide (ASO)-mediated correction for FXS.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Recipient: UMass Chan Medical School
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 15, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Recipient : UMass Chan Medical School
Deal Size : Undisclosed
Deal Type : Licensing Agreement
QurAlis Licenses New FXS Mechanism to Develop First Disease-Modifying Drug
Details : Under the licensing agreement, QurAlis explore the biology of FXS to determine and confirm relevant targets that could enable antisense oligonucleotide (ASO)-mediated correction for FXS.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 15, 2025
Details:
QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): QRL-101
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2025
Lead Product(s) : QRL-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants
Details : QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2025
Details:
QRL-101 is a potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS
Lead Product(s): QRL-101
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2025
QurAlis Reports QRL-101 Phase 1 Data on ALS & Epilepsy Biomarkers in Volunteers
Details : QRL-101 is a potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2025
Details:
QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): QRL-101
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2024
A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
Details : QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 03, 2024
Details:
QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in Amyotrophic lateral sclerosis patients.
Lead Product(s): QRL-201
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2024
QurAlis Progresses QRL-201 ALS Trial with First Dosed in Dose Range-Finding Phase
Details : QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in Amyotrophic lateral sclerosis patients.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 19, 2024
Details:
QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): QRL-101
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Centre for Human Drug Research
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 08, 2024
Lead Product(s) : QRL-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Centre for Human Drug Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2024
Details:
QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): QRL-101
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2024
Lead Product(s) : QRL-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants
Details : QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2024
Details:
QurAlis granted Lilly an exclusive, worldwide license to develop and commercialize QRL-204, a potentially best-in-class splice-switching ASO and other UNC13A-targeting compounds.
Lead Product(s): QRL-204
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Eli Lilly
Deal Size: $622.0 million Upfront Cash: $45.0 million
Deal Type: Licensing Agreement June 03, 2024
Lead Product(s) : QRL-204
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $622.0 million
Deal Type : Licensing Agreement
QurAlis Grants Lilly Exclusive Global License For QRL-204 In ALS, FTD
Details : QurAlis granted Lilly an exclusive, worldwide license to develop and commercialize QRL-204, a potentially best-in-class splice-switching ASO and other UNC13A-targeting compounds.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $45.0 million
June 03, 2024
Details:
QRL-201 is a first-in-class precision therapeutic product candidate aiming to restore STATHMIN-2 (STMN2) expression in ALS patients. ANQUR is the first-ever study to evaluate a therapy that rescues STMN2 expression in ALS patients.
Lead Product(s): QRL-201
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2023
Details : QRL-201 is a first-in-class precision therapeutic product candidate aiming to restore STATHMIN-2 (STMN2) expression in ALS patients. ANQUR is the first-ever study to evaluate a therapy that rescues STMN2 expression in ALS patients.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 06, 2023
Details:
The proceeds from the financing will fund clinical development of QRL-201 and QRL-101, QurAlis's lead product candidates in ALS. QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients.
Lead Product(s): QRL-201
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: EQT Life Sciences
Deal Size: $88.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 09, 2023
Details : The proceeds from the financing will fund clinical development of QRL-201 and QRL-101, QurAlis's lead product candidates in ALS. QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
